Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis - Wikidata - wikimedia - TriplyDB

Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis

Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis

http://www.wikidata.org/entity/Q28547636

about

Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.How to select a nanosimilar.Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.Iron sucrose: assessing the similarity between the originator drug and its intended copies.Medication practice in hospitals: are nanosimilars evaluated and substituted correctly?Intravenous Irons: From Basic Science to Clinical Practice

P2860

Q46611022-BB6F1982-2952-493F-9D64-9EBA24D747BD Q47762210-F4DFD4A3-E21F-458C-8DD4-9A06F329FF12 Q47805747-BD89FC36-4822-4068-AC76-810D7F266928 Q49720109-35EB92AF-671D-4AD3-9832-FF0A6294AECB Q52337431-957B449F-F90C-467C-92AD-C2C971E5B9FD Q57167424-28116292-B880-4BBF-8886-8F054A4C075B

P2860

Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis

http://www.wikidata.org/entity/Q28547636

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Efficiency of Original versus ...... s in Patients on Haemodialysis

@ast

Efficiency of Original versus ...... s in Patients on Haemodialysis

@en

Efficiency of Original versus ...... s in Patients on Haemodialysis

@nl

type

label

Efficiency of Original versus ...... s in Patients on Haemodialysis

@ast

Efficiency of Original versus ...... s in Patients on Haemodialysis

@en

Efficiency of Original versus ...... s in Patients on Haemodialysis

@nl

prefLabel

Efficiency of Original versus ...... s in Patients on Haemodialysis

@ast

Efficiency of Original versus ...... s in Patients on Haemodialysis

@en

Efficiency of Original versus ...... s in Patients on Haemodialysis

@nl

P1433

Q28547636-6D735DF2-3513-4695-91B8-1C9A16363663

P1476

Q28547636-BDED4CDD-3286-4842-A4AF-7CA14C911B38

P2093

Q28547636-0327EC08-476C-4EBE-9BC0-CECAAD70D5C6

Q28547636-4D99BF8F-D94F-45D7-A292-C5C9C3E62B2C

Q28547636-8FD3F4B2-15BF-4EB4-A5F2-9CAF6DF70DBE

Q28547636-BDA0C800-5B6F-404A-AEFF-D29A6A4A5C47

Q28547636-BDD715FA-C419-4FBB-B894-B136F457749E

Q28547636-CFE02834-B05D-4927-982A-83CA824272CE

Q28547636-FD7AC080-ED3E-4D9C-809E-5960AC8F9DB4

P2860

Q28547636-011D3AEB-0284-42FB-95EF-7B313DDBC810

Q28547636-0E214B5D-DDAD-4E6A-866C-ABDBED91DF56

Q28547636-13B854D7-620A-4663-952C-C68730D569E4

Q28547636-16CB9FFA-4B03-4526-A123-4653D0DA91E3

Q28547636-1EE47BB2-19A1-48A3-BA14-477103ACF311

Q28547636-2AEA80F2-BF44-42C4-B168-BB45C3754938

Q28547636-35CE0403-4DDE-4036-8437-0247B4D4083D

Q28547636-409287EA-8A74-48E7-BA9A-697A1C71B6DE

Q28547636-48F905B6-4C4E-4B07-948B-ED791B3CCFCA

Q28547636-4915156F-B917-494F-9FC5-54DA0CA17591

P304

Q28547636-52430215-84F9-43FB-A162-4FE3E735C394

P31

Q28547636-76BCAA6B-9955-4725-90B5-D57A9E47B371

P356

Q28547636-4B1E655F-F6F2-4DB7-96C6-0A500626A765

P407

Q28547636-BA3BDC52-C823-4AD4-9F7C-93658B11A82C

P433

Q28547636-A73E05D1-E38E-4176-A346-5DB14E67FDE1

P478

Q28547636-06CE6248-4D9C-44AE-9633-A14828F1F341

P577

Q28547636-E0E0D3A4-F306-4E83-B93D-37EB4D14BB70

P5875

Q28547636-35D5B69C-6044-458A-84BB-3463C601AEA1

P698

Q28547636-D68A92B4-B4BB-417D-9E33-FD4B444E0B06

P932

Q28547636-C211C678-83DF-46FB-BC4A-2DB52C3E1420

P356

JOURNAL.PONE.0135967

P1433

P1476

Efficiency of Original versus ...... s in Patients on Haemodialysis

@en

P2093

Alejandro Martin-Malo

http://www.w3.org/2001/XMLSchema#string

Maria Antonia Alvarez-Lara

http://www.w3.org/2001/XMLSchema#string

Maria Luisa Agüera

http://www.w3.org/2001/XMLSchema#string

Pedro Aljama

http://www.w3.org/2001/XMLSchema#string

Petra Canton

http://www.w3.org/2001/XMLSchema#string

Sagrario Soriano

http://www.w3.org/2001/XMLSchema#string

Victoria Eugenia Garcia-Montemayor

http://www.w3.org/2001/XMLSchema#string

P2860

Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review

Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis

Considerations and challenges in defining optimal iron utilization in hemodialysis

Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.

Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.

Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Intravenous iron exposure and mortality in patients on hemodialysis

A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.

Iron supplementation and mortality in incident dialysis patients: an observational study.

P304

e0135967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0135967

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281552772

http://www.w3.org/2001/XMLSchema#string

P698

26322790

http://www.w3.org/2001/XMLSchema#string

P932

4555833

http://www.w3.org/2001/XMLSchema#string